| scholarly article | Q13442814 |
| P2093 | author name string | John Londoño | |
| Gregory P Geba | |||
| Zafer E Ozturk | |||
| Robert Burton | |||
| Erluo Chen | |||
| Richard A Petruschke | |||
| Daryl K Najarian | |||
| Sandra Navarra | |||
| Bernard R Rubin | |||
| Joseph Antigua | |||
| Keith G Pryhuber | |||
| Margaret Lund | |||
| P2860 | cites work | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 |
| Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. | Q33178529 | ||
| Gastrointestinal effects of nonsteroidal anti-inflammatory therapy | Q33676713 | ||
| Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications | Q33813174 | ||
| Comparative toxicity of nonsteroidal anti-inflammatory drugs | Q33813195 | ||
| Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis | Q33875514 | ||
| The management of gout | Q40940712 | ||
| Crystal-induced arthritis: an overview | Q40972203 | ||
| Review article: COX-II inhibitors--a new generation of safer NSAIDs? | Q41467430 | ||
| Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial | Q43997545 | ||
| Effective management of gout: an analogy | Q77742220 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 598-606 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial | |
| P478 | volume | 50 |
| Q36870924 | 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis |
| Q36408778 | A Randomized, Controlled Trial to Assess the Efficacy of Arthroscopic Debridement in Combination with Oral Medication Versus Oral Medication in Patients with Gouty Knee Arthritis |
| Q35246568 | Acute gout: oral steroids work as well as NSAIDs |
| Q38303416 | Advances in pharmacotherapy for the treatment of gout |
| Q36301585 | An update on the treatment options for gout and calcium pyrophosphate deposition |
| Q38025456 | Canakinumab in gout |
| Q35092969 | Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study |
| Q21144617 | Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies |
| Q34847583 | Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib |
| Q34570225 | Clinical pharmacology of etoricoxib |
| Q34713083 | Clinical use and pharmacological properties of selective COX-2 inhibitors |
| Q33738046 | Colchicine for the treatment of gout |
| Q36349740 | Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs |
| Q36685004 | Comparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial. |
| Q34574741 | Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial |
| Q37807141 | Crystal Arthropathies: Recognizing and Treating “The Gouch” |
| Q38660829 | Current and future therapies for gout. |
| Q92287566 | Development and validation of a patient-reported gout attack intensity score for use in gout clinical studies |
| Q37910901 | Difficult-to-treat gouty arthritis: a disease warranting better management |
| Q60300771 | Do etoricoxib and indometacin have similar effects and safety for gouty arthritis? A meta-analysis of randomized controlled trials |
| Q24675150 | EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) |
| Q35671108 | Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis |
| Q38544457 | Enhanced analgesic activity by cyclodextrins - a systematic review and meta-analysis. |
| Q35166773 | Etoricoxib for arthritis and pain management |
| Q33213983 | Etoricoxib: a highly selective COX-2 inhibitor |
| Q34610283 | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis |
| Q52844811 | Foot pain, impairment, and disability in patients with acute gout flares: A prospective observational study. |
| Q83839631 | Gout |
| Q84110584 | Gout |
| Q90317380 | Gout |
| Q94370983 | Gout |
| Q22305834 | Gout in solid organ transplantation: a challenging clinical problem |
| Q24644156 | Gout--current diagnosis and treatment |
| Q37492596 | Gout--what are the treatment options? |
| Q37350841 | Gout. Novel therapies for treatment of gout and hyperuricemia |
| Q57245448 | Gouty Arthritis |
| Q29144218 | Hepatic gene expression response to acute indomethacin exposure |
| Q34508926 | Hyperuricemia and gout: diagnosis and therapy |
| Q56637250 | Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich) |
| Q37139512 | Management of gout |
| Q33635542 | Management of hyperuricemia in gout: focus on febuxostat. |
| Q37874889 | Managing your patient with gout: a review of treatment options |
| Q37553140 | Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative |
| Q36013803 | Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials |
| Q24193584 | Non-steroidal anti-inflammatory drugs for acute gout |
| Q38194896 | Optimizing current treatment of gout |
| Q38170977 | Outcome measures in acute gout: a systematic literature review |
| Q38268302 | Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review |
| Q37101535 | Overview of the management of acute gout and the role of adrenocorticotropic hormone |
| Q36832546 | Recent developments in crystal-induced inflammation pathogenesis and management. |
| Q36903272 | Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator |
| Q24243127 | Systemic corticosteroids for acute gout |
| Q24658037 | Taking the stress out of managing gout |
| Q37910891 | The challenges of gout management in the elderly |
| Q28176535 | The safety of rofecoxib |
| Q47177948 | Update on colchicine, 2017. |
| Q34090789 | Update on gout: new therapeutic strategies and options |
| Q80380615 | [Uratic gout] |
Search more.